These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38229356)

  • 21. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
    van Vollenhoven RF; Lee EB; Fallon L; Zwillich SH; Wilkinson B; Chapman D; DeMasi R; Keystone E
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):71-79. PubMed ID: 29696833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention.
    Pope J; Finckh A; Silva-Fernández L; Mandl P; Fan H; Rivas JL; Valderrama M; Montoro M
    Open Access Rheumatol; 2024; 16():115-126. PubMed ID: 38883150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
    Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
    Gabay C; Emery P; van Vollenhoven R; Dikranian A; Alten R; Pavelka K; Klearman M; Musselman D; Agarwal S; Green J; Kavanaugh A;
    Lancet; 2013 May; 381(9877):1541-50. PubMed ID: 23515142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
    Fleischmann R; Kremer J; Cush J; Schulze-Koops H; Connell CA; Bradley JD; Gruben D; Wallenstein GV; Zwillich SH; Kanik KS;
    N Engl J Med; 2012 Aug; 367(6):495-507. PubMed ID: 22873530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Yishen Tongbi decoction versus methotrexate in patients with active rheumatoid arthritis: A double-blind, randomized, controlled, non-inferiority trial.
    Xu J; Zhang L; Xu Y; Yu J; Zhao L; Deng H; Li M; Zhang M; Lei X; Hu C; Jiao W; Dai Z; Liu L; Chen G
    Phytomedicine; 2023 Apr; 112():154704. PubMed ID: 36796186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.